PDCD1 and non-small cell lung carcinoma: A study reported in 2018 assessed the combination of sintilimab, an anti-PD-1 antibody, with a multi-target anti-angiogenic tyrosine kinase inhibitor (anlotinib) as a first-line therapy for NSCLC patients.